1703 related articles for article (PubMed ID: 27605551)
21. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Ong SY; Pak S; Mei M; Wang Y; Popplewell L; Baird JH; Herrera AF; Shouse G; Nikolaenko L; Zain J; Godfrey J; Htut M; Aribi A; Spielberger R; Mansour J; Forman SJ; Palmer J; Budde LE
Am J Hematol; 2023 Nov; 98(11):1751-1761. PubMed ID: 37668287
[TBL] [Abstract][Full Text] [Related]
22. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Santini G; Nati S; Spriano M; Gallamini A; Pierluigi D; Congiu AM; Truini M; Rubagotti A; Chisesi T; Vimercati R; Rossi E; Sertoli MR; Mattei D; Marino G; Gobbi M
Haematologica; 2001 Mar; 86(3):282-6. PubMed ID: 11255275
[TBL] [Abstract][Full Text] [Related]
23. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
[TBL] [Abstract][Full Text] [Related]
24. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.
Turtle CJ; Riddell SR; Maloney DG
Clin Pharmacol Ther; 2016 Sep; 100(3):252-8. PubMed ID: 27170467
[TBL] [Abstract][Full Text] [Related]
25. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.
Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ
J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905
[TBL] [Abstract][Full Text] [Related]
26. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma.
Denlinger N; Song NJ; Zhang X; Jeon H; Peterson C; Wang Y; Reynolds K; Bolz RM; Miao J; Song C; Wu D; Chan WK; Bezerra E; Epperla N; Voorhees TJ; Brammer J; Kittai AS; Bond DA; Sawalha Y; Sigmund A; Reneau JC; Rubinstein MP; Hanel W; Christian B; Baiocchi RA; Maddocks K; Alinari L; Vasu S; de Lima M; Chung D; Jaglowski S; Li Z; Huang X; Yang Y
Blood Adv; 2024 Jun; 8(12):3140-3153. PubMed ID: 38607381
[TBL] [Abstract][Full Text] [Related]
27. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Heczey A; Louis CU; Savoldo B; Dakhova O; Durett A; Grilley B; Liu H; Wu MF; Mei Z; Gee A; Mehta B; Zhang H; Mahmood N; Tashiro H; Heslop HE; Dotti G; Rooney CM; Brenner MK
Mol Ther; 2017 Sep; 25(9):2214-2224. PubMed ID: 28602436
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
29. Has the shortage of fludarabine altered the current paradigm of lymphodepletion in favor of bendamustine?
Filioglou D; Husnain M; Khurana S; Simpson RJ; Katsanis E
Front Immunol; 2023; 14():1329850. PubMed ID: 38077398
[TBL] [Abstract][Full Text] [Related]
30. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
[TBL] [Abstract][Full Text] [Related]
31. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
Cao G; Lei L; Zhu X
Medicine (Baltimore); 2019 Oct; 98(42):e17506. PubMed ID: 31626107
[TBL] [Abstract][Full Text] [Related]
32. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
[TBL] [Abstract][Full Text] [Related]
33. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Riddell SR; Maloney DG; Turtle CJ
Blood; 2019 Aug; 134(7):636-640. PubMed ID: 31648294
[TBL] [Abstract][Full Text] [Related]
34. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
Front Immunol; 2022; 13():969660. PubMed ID: 36059523
[TBL] [Abstract][Full Text] [Related]
35. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.
Rossi J; Paczkowski P; Shen YW; Morse K; Flynn B; Kaiser A; Ng C; Gallatin K; Cain T; Fan R; Mackay S; Heath JR; Rosenberg SA; Kochenderfer JN; Zhou J; Bot A
Blood; 2018 Aug; 132(8):804-814. PubMed ID: 29895668
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
[TBL] [Abstract][Full Text] [Related]
37. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.
Kekre N; Hay KA; Webb JR; Mallick R; Balasundaram M; Sigrist MK; Clement AM; Nielsen JS; Quizi J; Yung E; Brown SD; Dreolini L; Waller DD; Smazynski J; Gierc NS; Loveless BC; Clark K; Dyer T; Hogg R; McCormick L; Gignac M; Bell S; Chapman DM; Bond D; Yong S; Fung R; Lockyer HM; Hodgson V; Murphy C; Subramanian A; Wiebe E; Yoganathan P; Medynski L; Vaillan DC; Black A; McDiarmid S; Kennah M; Hamelin L; Song K; Narayanan S; Rodrigo JA; Dupont S; Hawrysh T; Presseau J; Thavorn K; Lalu MM; Fergusson DA; Bell JC; Atkins H; Nelson BH; Holt RA
Front Immunol; 2022; 13():1074740. PubMed ID: 36601119
[TBL] [Abstract][Full Text] [Related]
38. Rational Alternatives to Fludarabine and Cyclophosphamide-Based Pre-CAR Lymphodepleting Regimens in the Pediatric and Young Adult B-ALL Setting.
Green S; Schultz L
Curr Oncol Rep; 2023 Aug; 25(8):841-846. PubMed ID: 37099243
[TBL] [Abstract][Full Text] [Related]
39. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E; Marin D; Banerjee P; Macapinlac HA; Thompson P; Basar R; Nassif Kerbauy L; Overman B; Thall P; Kaplan M; Nandivada V; Kaur I; Nunez Cortes A; Cao K; Daher M; Hosing C; Cohen EN; Kebriaei P; Mehta R; Neelapu S; Nieto Y; Wang M; Wierda W; Keating M; Champlin R; Shpall EJ; Rezvani K
N Engl J Med; 2020 Feb; 382(6):545-553. PubMed ID: 32023374
[TBL] [Abstract][Full Text] [Related]
40. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
